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Abstract
Objective: To investigate the best criteria for discriminating 
fetuses with isolated posterior urethral valves from those 
theoretically not eligible for fetal treatment because of com-
plex megacystis, high chance of spontaneous resolution, 
and urethral atresia. Methods: A retrospective national study 
was conducted in fetuses with megacystis detected before 
17 weeks’ gestation (early megacystis). Results: In total, 142 
cases with fetal megacystis were included in the study: 52 
with lower urinary tract obstruction, 29 with normal micturi-
tion at birth, and 61 with miscellaneous syndromal associa-
tions, chromosomal and multiple structural abnormalities 
(complex megacystis). Only a nuchal translucency > 95th 
centile, and not a longitudinal bladder diameter ≤15 mm 
(p = 0.24), significantly increased the risk of complex mega-
cystis (p < 0.01). Cases with a high chance of spontaneous 
resolution were identified by using the cut-off of 12 mm, as 
demonstrated in a previous study, and the finding of an as-
sociated umbilical cord cyst carried a high-risk of urethral 
atresia (odds ratio: 15; p = 0.026), an unfavorable condition 
for antenatal treatment. An algorithm encompassing these 
three criteria demonstrated good accuracy in selecting fe-
tuses theoretically eligible for fetal treatment (specificity 
73%; sensitivity 92%). Conclusions: Cases theoretically eli-
gible for early fetal therapy are those with normal nuchal 
translucency, a longitudinal bladder diameter > 12 mm, and 
without ultrasound evidence of umbilical cord cysts.
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Introduction
An enlarged urinary bladder, also known as megacys-
tis, is a rare ultrasound finding observed in 0.06% [1] of 
first-trimester pregnancies. This ultrasound anomaly is 
rather obvious and therefore, it is considered one of the 
anomalies “expected to be detected” at the currently 
widely performed first-trimester scans. In 1996, Sebire 
et al. [1] defined as megacystis a longitudinal bladder 
diameter (LBD) greater than 7 mm between 11 and 14 
weeks’ gestation. The authors described three possible 
evolutions with different outcomes: chromosomal ab-
normalities, antenatal spontaneous resolution, or pro-
gression to obstructive uropathy [1]. In this historical 
study, the authors suggested to base the antenatal coun-
seling and workup on the LBD. If this is between 7 and 
15 mm, fetal karyotype is recommended, as the majority 
of chromosomal anomalies falls in this group, and if the 
karyotype is normal, a spontaneous resolution will oc-
cur in 90% of cases; while in cases with LBD > 15 mm, 
the prognosis is poor, due to a high incidence of lower 
urinary tract obstruction (LUTO) and subsequent ob-
structive uropathy.
After the exclusion of cases where spontaneous resolu-
tion is likely, first-trimester counseling of fetal megacystis 
has traditionally been negative, due to the lack of available 
early therapeutic options [2]. Nowadays, thanks to tech-
nical improvements, early fetal therapy has however be-
come plausible [3–5], as it appears that an early interven-
tion is the only strategy potentially capable of preventing 
the occurrence of renal damage in the very few cases with 
truly isolated posterior urethral valves (PUV) [3, 6, 7]. In 
the attempt to identify these rare cases – should parents 
not consider termination of pregnancy as an option – the 
challenge remains which criteria should be used to effec-
tively detect first-trimester fetuses with complex mega-
cystis and very poor prognosis, on the one hand, and 
those with a high chance of spontaneous resolution and 
favorable prognosis, on the other.
As criterion for triaging fetuses with normal chromo-
somes and eligible for early intervention, the value of an 
LBD greater than 15 mm has not yet been extensively test-
ed. Moreover, it is known that, besides chromosomal 
anomalies, there are other severe causes of complex 
megacystis that ideally should be identified as soon as 
possible in order to inform parents on the expected poor 
prognosis. To date, no effective criteria have been formu-
lated for their identification. Conversely, regarding the 
prediction of spontaneous resolution, we have recently 
confirmed the accuracy of the LBD measurement and 
suggested a new cut-off, i.e., 12 mm, rather than the clas-
sic 15 mm, as a more accurate predictor [8].
The aim of this study is therefore to construct a man-
agement algorithm aimed at excluding fetuses with com-
plex megacystis or likely to undergo a spontaneous reso-
lution, and at effectively identifying the very few cases 
with isolated PUV, theoretically eligible for early fetal in-
tervention. 
Methods 
This was a retrospective multicenter study carried out at the 
Fetal Medicine Units of the eight University Hospitals in the Neth-
erlands. Cases were collected at the Erasmus Medical Center, Aca-
demic Medical Center, Amsterdam, and at the University Medical 
Center, Maastricht from 2000 to 2015, between 2004 and 2015 at 
the University Medical Center Groningen and at the Radboud 
University Medical Center, Nijmegen, and between 2007 and 2014 
in the remaining centers. Fetal megacystis was defined as an LBD 
≥7 mm [1]. 
Collected prenatal data of referred cases included: gestational 
age at diagnosis, LBD, and eventual additional anomalies. The LBD 
was obtained from a midsagittal view of the fetus, by measuring the 
distance from fetal bladder dome to bladder neck. Umbilical cord 
cysts (UCC) were defined as anechoic structures within the um-
bilical cord eventually described at the ultrasound medical report. 
The nuchal translucency (NT) was considered increased if greater 
than the 95th percentile for the gestational age [9]. Final diagnosis 
was based on postnatal investigations or postmortem examina-
tions. Three main categories of final diagnosis were identified: cas-
es with LUTO, cases with complex megacystis, and cases with nor-
mal voiding at birth or isolated urological anomaly. The group with 
complex megacystis included cases with miscellaneous syndromal 
associations, chromosomal and multiple structural abnormalities. 
In 91 cases, a final diagnosis was not established because the preg-
nancy was terminated, the parents did not consent for the autopsy, 
and the prenatal investigations were not diagnostic.
In order to identify the candidates for intrauterine surgery, an-
tenatal variables were investigated for their capability of predicting 
these 4 scenarios: only chromosomal abnormalities; chromosomal 
abnormalities or other conditions with poor prognosis (complex 
megacystis); urethral atresia, considered as a very severe form of 
LUTO; and spontaneous resolution, whereby megacystis is a tem-
porary presentation and the prognosis is mostly benign. The pre-
dictors were investigated by using a bivariate logistic regression 
analysis and the association was described by odds ratios (OR) and 
95% confidence intervals (CI). All statistical analyses were per-
formed using SPSS 22.
Results
During the study period, 233 pregnancies were re-
ferred to one of the eight academic centers in the Nether-
lands owing to fetal megacystis, detected between the 
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10th and 17th week of gestation. A clear final diagnosis 
was possible in 142 cases and included 61 fetuses with 
complex megacystis, 52 with isolated LUTO, and 29 with 
normal voiding at birth or isolated urological anomaly 
(Fig. 1). The group with complex megacystis (n = 61) pre-
sented miscellaneous syndromal associations, chromo-
somal and multiple structural abnormalities and included 
28 cases with chromosomal abnormalities (46%), 18 fe-
tuses with anorectal malformations (30%), and 15 cases 
with other multiple congenital anomalies (25%). LBD 
and NT were measured at the first ultrasound examina-
tion in 124 and 110 pregnancies, respectively. 
The most common chromosomal abnormality was tri-
somy 18 (n = 13; 46%), followed by trisomy 21 (n = 3; 
11%), trisomy 13 (n = 3; 11%), Turner syndrome (n = 3; 
11%), and other chromosomal abnormalities (n = 6; 21%). 
The median LBD in fetuses with trisomy 13, 18, and 21 
was 8.1 mm, 13 mm, and 24 mm, respectively (Table 1). 
In total, the LBD was ≤15 mm in 42 cases and > 15 mm in 
82 cases, and the incidence of chromosomal abnormali-
ties was 36% (15/42) in the first group and 13% (11/82) in 
the second group with LBD > 15 mm. Forty-five percent 
of fetuses with trisomy 18 and 21 had an LBD > 15 mm. 
Out of 28 cases with abnormal karyotype, 57% (16/28) 
had an LBD ≤15 mm and 43% (12/28) had an LBD > 15 
mm. The accuracy of the classic 15-mm cut-off for the 
LBD was tested and compared to the accuracy of the NT 
measurement for identifying fetuses with complex mega-
cystis. The classic criteria of an LBD ≤15 mm slightly in-
creased the risk of chromosomal abnormalities (OR: 0.3 
Early megacystis
(n = 142)
Normal voiding at birth 
or isolated urological 
anomaly 
(n = 29)
LUTO 
(n = 52)
Urethral atresia (n = 19) 
PUV (n = 17)
Urethral stenosis (n = 16)
Complex megacystis 
(n = 61)
Chromosomal abnormalities (n = 28)
ANM (n = 18)
MCA and other congenital syndromes (n = 15)
Fig. 1. Study population. LUTO, lower urinary tract obstruction; PUV, posterior urethral valves; ANM, anorec-
tal malformations; MCA, multiple congenital anomalies.
Table 1. Nuchal translucency (NT) and longitudinal bladder diameter (LBD) according to final diagnosis
NT >95th centile LBD, mm GA at diagnosis, weeks
LUTO (n = 52) 6% 32 (14) 15 (1.7)
Syndromes (n = 61) 23% 20 (13) 13 (1.6)
Chromosomal abnormalities (n = 28) 50% 15 (8) 13 (1.2)
Trisomy 13 (n = 3) 1.5 (1–2) 8.1 (8–10) 12 (12–13)
Trisomy 18 (n = 13) 4.2 (3–12) 13.0 (7–32) 13 (12–15)
Trisomy 21 (n = 3) 4.3 (4–5) 24.0 (8–29) 13 (13–17)
p value trisomy 13 – trisomy 18 0.06
p value trisomy 13 – trisomy 21 0.35
p value trisomy 18 – trisomy 21 0.25
Categorical variables are expressed as percentage (%). Numerical variables are expressed as mean (standard 
deviation) or median (range). LUTO, lower urinary tract obstruction.
Fontanella et al.Fetal Diagn Ther4
DOI: 10.1159/000488282
[95% CI: 0.1–0.7], p = 0.01), whereas only an NT > 95th 
centile, and not an LBD ≤15 mm, significantly increased 
the risk of complex megacystis in general, including fe-
tuses with miscellaneous syndromal associations, chro-
mosomal and multiple structural abnormalities (NT > 
95th centile: OR: 13.7 [95% CI: 3.8–48.5], p < 0.001; LBD 
≤15 mm: OR: 0.6 [95% CI: 0.3–1.4], p = 0.24).
In order to define an algorithm capable of selecting fe-
tuses with isolated PUV, 37 fetuses with NT > 95th centile 
and at risk of complex megacystis were excluded from 
further analysis. 
The chance of an antenatal spontaneous resolution 
was then evaluated by measuring the LBD and using the 
new cut-off of 12 mm, as suggested by our previous study 
[8]. Therefore, another 39 cases with LBD ≤12 mm were 
considered to have a high chance of spontaneous resolu-
tion and excluded. 
Of the 66 remaining cases with suspected isolated 
LUTO, 29 cases presented an associated UCC at the ul-
trasound examination, and 15 cases in total (7 female and 
8 male fetuses; 23%) showed a urethral atresia at the post-
mortem examination. The evidence of an associated UCC 
significantly increased the risk of urethral atresia with an 
OR of 15 (p = 0.026). 
These three antenatal parameters (NT > 95th centile, 
LBD > 12 mm, and evidence of UCC) showed a good pre-
dictive value for each outcome (complex megacystis, 
spontaneous resolution, and urethral atresia, respective-
ly), as reported in Table 2. For each parameter, the OR 
was higher if calculated by following our management 
algorithm (Table 2; Fig.  2) rather than considering the 
whole population. 
Among fetuses with early megacystis, an algorithm en-
compassing these three criteria (Fig. 2) can guide coun-
seling and management of this condition and discrimi-
nate fetuses theoretically eligible for fetal treatment with 
a specificity and sensitivity of 73% and 92%, respectively.
Table 2. Odds ratio of nuchal translucency (NT) >95th centile, longitudinal bladder diameter (LBD) >12 mm, and evidence of umbilical 
cord cysts (UCC) for predicting complex megacystis, spontaneous resolution, and urethral atresia, respectively
Odds ratio obtained by considering 
the whole population
Odds ratio obtained by following the  
proposed management algorithm
NT >95th centile for complex megacystis 14 (p < 0.001) 14 (p < 0.001)
LBD >12 mm for spontaneous resolution 10 (p < 0.001) 16 (p < 0.001)
Evidence of UCC for urethral atresia 7 (p = 0.003) 15 (p = 0.026)
Early megacystis
9% isolated PUV (13/142)
NT ≥95th centile
0% isolated PUV (0/105)
NT <95th centile
12% isolated PUV (13/105)
LBD <12 mm
0% isolated PUV (0/39) 
LBD >12 mm
18% isolated PUV (13/66)
With associated UCC
3% isolated PUV (1/29)
Without associated UCC
32% isolated PUV (12/37)
Fig. 2. Decision tree analysis for detecting 
isolated posterior urethral valves (PUV) in 
fetuses with early megacystis. Out of 17 cas-
es with isolated PUV, 4 were excluded from 
the algorithm as their longitudinal bladder 
diameter (LBD) measurement was not 
available. NT, nuchal translucency; UCC, 
umbilical cord cyst.
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Discussion 
This study shows that in fetuses with early megacystis, 
the best criteria to guide the parental counseling and se-
lect cases with isolated PUV are: a normal NT, an LBD 
greater than 12 mm, and absence of UCC. These criteria 
demonstrated good accuracy in evaluating the risk of 
complex megacystis, spontaneous resolution, and ure-
thral atresia, and in selecting those fetuses theoretically 
eligible for antenatal treatment. 
Historically, an LBD greater or lower than 15 mm was 
used to evaluate the chance of chromosomal abnormali-
ties or spontaneous resolution [1, 10, 11]. In this study, 
we showed that an enlarged NT, rather than the LBD 
measurement, significantly increased the risk of complex 
megacystis, including fetuses with miscellaneous syndro-
mal associations, chromosomal and multiple structural 
abnormalities carrying a poor prognosis. We recently 
demonstrated that the optimal LBD cut-off to predict the 
chance of spontaneous resolution of megacystis is 12 mm, 
rather than 15 mm. Therefore, to sum up, the LBD should 
be considered only as predictor of spontaneous resolu-
tion [8], while the NT measurement should be taken into 
account as predictor of complex megacystis.
Further support to this finding is provided by the pro-
spective study by Syngelaki et al. [12], including 108,982 
pregnancies undergoing first-trimester screening. This 
large study reported a similar distribution of chromo-
somal abnormalities in cases with megacystis with LBD 
> 15 or ≤15 mm, and suggested to base the decision for in- 
vasive testing on the results of the combined test or, alter-
natively, offer cfDNA [12]. This new approach is at vari-
ance with the commonly used management protocol for 
first-trimester megacystis, based on the study by Liao et 
al. [10]. The discrepancy in results is probably due to the 
different distribution in chromosomal anomalies be-
tween our study, that of Syngelaki et al. [12], and Liao et 
al.’s study [10]. In fact, similarly to our study, Syngelaki 
et al. [12] reported trisomy 18 as the most common chro-
mosomal abnormality in fetuses with first-trimester 
megacystis (5/15; 33%), followed by trisomy 21 (4/15; 
27%) and trisomy 13 (3/15; 20%) [12], whereas in the 
study by Liao et al. [10], the most common chromosomal 
abnormality in fetuses with megacystis was trisomy 13 
(17/29; 59%), followed by trisomy 18 (7/29; 24%) and, as 
least frequent, by trisomy 21, found in only 7% of cases 
(2/29; 7%). In this study, we observed that, in fetuses with 
trisomy 13, megacystis is typically mildly enlarged (mean 
LBD: 8.7 mm), whereas cases with trisomy 18 and 21 
show a more severe degree of bladder distension (mean 
LBD: 20 and 15 mm, respectively). To date, the patho-
logical background of fetal obstructive uropathy in triso-
mic fetuses has not yet been fully clarified [13]. We spec-
ulate that, among trisomies, there may be a different un-
derlying cause of megacystis, with a varying degree of 
bladder enlargement, depending on the type of chromo-
somal abnormality. Hence, an obstructive uropathy is 
more commonly reported in fetuses with trisomy 18 and 
21, but rarely in trisomy 13 [13–15]. Therefore, the differ-
ent prevalence of trisomies between the studies may ex-
plain the divergent results. In light of the prospective na-
ture and the size of Syngelaki et al.’s study [12], this is 
more likely to reflect the true distribution of chromosom-
al anomalies in fetuses with first-trimester megacystis.
Since the study by Liao et al. [10], there has been an 
increased interest in fetal therapy for LUTO. Recent stud-
ies have suggested that antenatal treatment improves 
perinatal survival, but with little effect on postnatal renal 
function [16–18]. This is probably due to the fact that re-
nal parenchyma is in most cases already damaged at the 
time of fetal intervention. Animal studies have demon-
strated a correlation between early LUTO and severity of 
renal damage, thus suggesting that an early treatment, al-
though technically more challenging, may potentially im-
prove the outcome [19, 20]. New therapeutic attempts, 
based on recent technical improvements, aim at sparing 
renal function starting from 14–16 weeks’ gestation [3–
5]. In this context, it has become extremely important to 
be able to select, as early as possible, fetuses eligible for 
timely treatment, should the parents choose for this op-
tion. Among cases with LUTO, fetuses with urethral atre-
sia often present other associated developmental abnor-
malities and a poorer prognosis, compared to those with 
PUV [21]. Furthermore, in cases with urethral atresia, fe-
tal cystoscopy, which specifically attempts to ablate the 
PUV, is not indicated [17]. Urethral atresia is commonly 
considered in female fetuses without keyhole sign. How-
ever, in our cohort, after excluding fetuses at risk of com-
plex megacystis and spontaneous resolution, half of the 
fetuses (8/15) with urethral atresia were male, and other 
studies have already demonstrated that the keyhole sign 
is not a reliable predictor of PUV [22]. No previous study 
has so far found other reliable antenatal signs for this sub-
tle differential diagnosis in the first trimester.
In the literature, UCC are reported at the first-trimes-
ter scan in 0.4–3.4% of cases [23]. In our cohort, we found 
a UCC in 12% (29/233) of fetuses with early megacystis. 
Previous studies have suggested that UCC may be an ear-
ly sign of severe obstructive uropathy [24, 25]. This study 
is the first to clearly indicate that evidence of a UCC in 
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conjunction with a megacystis is a strong marker of ure-
thral atresia, already from the first trimester of pregnan-
cy. A plausible explanation for the association between 
megacystis and urethral atresia is that during the first 
stages of life, the bladder is connected with the umbilical 
cord through the allantois, which obliterates at 6–12 
weeks’ gestation to form the urachus, a fibromuscular tu-
bular structure located between the apex of the bladder 
and the umbilical cord insertion. An abnormally distend-
ed urinary bladder could prevent the closure of the allan-
tois and eventually lead to a cystic dilatation of the allan-
tois or of the umbilical cord [25, 26]. This is more likely 
to occur in fetuses with an early and severe bladder en-
largement, as it is the case in the setting of urethral atresia. 
This is another useful element to take into account when 
counseling parents on both prognosis and therapeutic 
options of fetal megacystis. 
An important limitation of this study in assessing the 
real prevalence of UCC is that a complete examination of 
the umbilical cord, from placental to fetal insertion, was 
not routinely performed. We speculate that if this would 
have been done, theoretically even more UCC may have 
been seen. A second limitation is that, in this national co-
hort, the parental counseling was guided by Liao et al.’s 
results [10] and fetal karyotype was mainly recommend-
ed to fetuses with LBD ≤15 mm. Although this approach 
may have affected our results, the impact of this bias has 
been minimized by establishing the final diagnosis ac-
cording to both postnatal and postmortem examinations, 
rather than only considering antenatal scans and fetal 
karyotype.
To summarize, we propose a new approach in the 
management and counseling of fetuses with early mega-
cystis. Karyotyping should be offered more liberally and, 
for the detection of fetuses with complex megacystis, the 
focus should be on the NT rather than on the LBD. More-
over, cases with a high chance of spontaneous resolution 
should be identified by using the cut-off of 12 mm, as pre-
viously demonstrated. Besides this, the finding of a UCC 
should be regarded as an unfavorable prognostic factor 
because of its association with urethral atresia. Therefore, 
a thorough routine inspection of the umbilical cord 
should be carried out in all cases of megacystis to identify 
fetuses at risk of urethral atresia. We have summarized 
these recommendations in a flowchart to guide the ante-
natal workup and counseling in early megacystis cases, 
aiming at identifying fetuses with PUV only, theoretical-
ly eligible for early antenatal treatment.
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Appendix
Histogram of longitudinal bladder diameter measurement.
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